Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta‐analysis

Abstract This meta‐analysis aims to assess the clinical effectiveness of combination therapy with montelukast sodium for the treatment of cough variant asthma (CVA) in children, intending to provide clinical evidence and data to guide the selection of clinical therapy. A literature review was conducted using numerous databases, including China National Knowledge Infrastructure (CNKI), Wanfang database, Embase, PubMed, and Web of Science, from inception to December 2023. Trials meeting the criteria for the combined treatment of montelukast sodium for CVA in children were included. Stata 16.0 software was utilized for meta‐analysis. The combined treatment group received montelukast sodium in addition to the control group, while the control group received budesonide, fluticasone propionate, salmeterol‐fluticasone, or ketotifen alone. This investigation included 18 papers. All subjects were from the Chinese population. Compared to the control group, the combined treatment group demonstrated a higher effective rate (relative ratio [RR] = 1.23, 95% confidence interval [CI]: 1.18–1.29, p < .001), but no difference in the incidence of adverse reactions (RR = 0.65, 95% CI: 0.42–1.02, p = .060) after treatment. Moreover, the peak expiratory flow (PEF) (SMD = 1.69, 95% CI: 1.09–2.30, p < .001), forced vital capacity (FVC) (SMD = 1.67, 95% CI: 0.94–2.39, p < .001), forced expiratory volume in 1 s (FEV1) (SMD = 1.74, 95% CI: 1.09–2.40, p < .001), and FEV1/FVC (SMD = 1.84, 95% CI: 0.41–3.28, p = .012) were significantly higher in the combined treatment group than in the control group after treatment. Compared with the control group, the levels of tumor necrosis factor‐α (SMD = −2.38, 95% CI: −3.22 to −1.55, p < .001), IL‐4 (SMD = −2.65, 95% CI: −3.26 to −2.04, p < .001), and IgE (SMD = −2.98, 95% CI: −3.24 to −2.72, p < .001) were significantly lower in the combined treatment group after treatment. The combined use of montelukast sodium in the treatment of pediatric CVA in China is associated with a significant clinical effect, making it a reasonable therapeutic approach.